Servier and Day One Biopharmaceuticals announce acquisition to expand Servier's rare oncology portfolio
Acquisition positions Servier as a leader in pediatric low-grade glioma and expands its pipeline with programs targeting adult and pediatric cancers with high unmet needs. Transaction represents total equity value of approximately $2.5 billion....